| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Significant advancements in cancer treatment are shaping the landscape of Gilead Sciences' product and service development, particularly through innovations in cell therapy for blood cancer. The development of new therapies like Livdelzi showcases the company's commitment to innovation and positive patient outcomes, especially in liver disease treatment. However, challenges in drug development, notably with Trodelvy in breast cancer, highlight the difficulties Gilead faces in meeting study goals. Balancing these positive advancements against drug development challenges will be crucial for the company's ongoing success. |
| The price action of Gilead Sciences (GILD) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The market sentiment at 0.1 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for GILD since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.3, and the negative at -0.2 on 2025-11-07. The forces of and Valuation Sentiment (-1) will drive down the price. The forces of Stock Price Trend (0), Sector Price Trend (0), Price Level Sentiment (0), Option Sentiment (0), Market Risk Appetite (0), and Sentiment towards Fundamentals (1.8) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| GILD | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-07 | 0%(0%) | 0 | 0% | 0.1 | 1.8 | -1 | |||||||
| 2025-11-06 | 0%(0%) | 0 | 0% | 0.5 | 3.7 | -1 | |||||||
| 2025-11-05 | 0%(0%) | 0 | 0% | 0.6 | 4.3 | -1 | |||||||
| 2025-11-04 | 0%(0%) | 0 | 0% | 0.4 | 3.5 | -1 | |||||||
| 2025-11-03 | 0%(0%) | 0 | 0% | 0.4 | 3.5 | -1 | |||||||
| 2025-11-02 | 0%(0%) | 0 | 0% | 0.3 | 3 | -1 | |||||||
| 2025-11-01 | 0%(0%) | 0 | 0% | 0.3 | 3 | -1 | |||||||
| 2025-10-31 | 0%(0%) | 0 | 0% | 0.3 | 3 | -1 | |||||||
| 2025-10-30 | 0%(0%) | 0 | 0% | 0.3 | 2.5 | -1 | |||||||
| 2025-10-29 | 0%(0%) | 0 | 0% | -0 | 0.8 | -1 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-11-07 17:08:17 Gilead's position in the market and its efficacy in providing treatment options are being closely analyzed amidst mixed trial results. |
| 2025-11-07 17:08:17 Articles reflect the impact of regulatory outcomes and clinical trial results on Gilead's drug pipeline, particularly for Trodelvy. |
| 2025-11-07 17:08:17 The stock performance of Gilead Sciences has shown a decline, as indicated by recent stock price drops. |
| 2025-11-07 17:08:17 Gilead's Livdelzi® drug shows sustained efficacy in treating primary biliary cholangitis, demonstrating a positive impact on patient health outcomes. |
| 2025-11-07 17:08:17 Recent articles highlight difficulties faced by Gilead in developing its breast cancer drug Trodelvy, which failed to meet key study goals. |